

FINAL PROGRAMME

BHIVA Autumn Conference

16–17 November 2017

QEI Centre
London

Preceded by

BHIVA Hepatology Highlights for the Healthcare Specialist

in collaboration with the
British Viral Hepatitis Group (BVHG)
Wednesday 15 November 2017



www.bhiva.org

#BHIVA2017



Follow us on social media

Download the
BHVA Conferences App



A CASE IN POINT

THERAPY DECISIONS IN AN ERA OF CHOICE

Friday 17 November 2017
09:00-10:00

Fleming room
(third floor),
Queen Elizabeth II
Conference Centre,
London

A Gilead-sponsored
symposium at the
BHIVA Autumn
Conference 2017

Introduced and chaired by:

Dr Andrew Ustianowski
North Manchester General Hospital

Speakers:

Dr James Cockburn
Royal Sussex County Hospital, Brighton

Professor Bruce Hendry
King's College London

Dr Iain Reeves
Homerton University Hospital, London

CPD credit applied for

HIV/UK/17-08/PMAR/1827f October 2017



Organised and funded by Gilead Sciences Ltd

INTRODUCTION

CONTENTS

BHIVA Committees.....	4	Conference Information.....	13–14
Programme Summary.....	5	Sponsors and Exhibitors Floorplan.....	15
Programme.....	6–10	Speaker Biographies.....	16–20
Sponsors' Satellite Symposia and Lunchtime Workshops	11	Forthcoming Events.....	21–23

Dear Colleague

Welcome to the **BHIVA Autumn Conference**, which this year will be preceded by the **BHIVA Hepatology Highlights for the Healthcare Specialist**.

Again, both events are held at the prestigious QEI Conference Centre, in the heart of London.

I would like to thank Dr Laura Waters (Chair of the Conferences Subcommittee), Dr Iain Reeves (Conference Local Host) and all the members of the Conferences Subcommittee, for their efforts in preparing an excellent programme for this conference.

The conference sessions will cover a wide range of important topics relevant to HIV. Please refer to the programme pages for a full schedule of topics and timings.

The BHIVA Annual General Meeting will be held on Friday 17 November prior to lunch. I would encourage all BHIVA members to attend this meeting, as it provides a forum to present any points they may have to the BHIVA Officers and members of the Executive Committee.

Finally, we would like to thank our sponsors for their continued support of the Association, which assists greatly with covering some of the costs incurred in organising this conference.

We very much hope you enjoy the programme and find it relevant to both your educational and practical needs.

Professor Chloe Orkin
Chair, British HIV Association



CONFERENCE VENUE

BHIVA HIV/Hepatitis Conference		QEI Centre, Broad Sanctuary, London SW1P 3EE
Registration	Sanctuary Foyer, Ground Floor	
Lecture Theatre.....	Abbey, Fourth Floor	
Exhibition and Catering.....	Rutherford, Fourth Floor	
BHIVA Autumn Conference		QEI Centre, Broad Sanctuary, London SW1P 3EE
Registration	Sanctuary Foyer, Ground Floor	
Lecture Theatre (all BHIVA sessions).....	Fleming, Third Floor	
Sponsors Lunchtime Workshops.....	Abbey, Fourth Floor	
BHIVA Lunchtime Workshops.....	Fleming, Third Floor	
Satellite Symposia.....	Fleming, Third Floor	
Exhibition	Britten, Third Floor	
Lunch and Refreshments	Britten, Third Floor	
Speakers' Presentation Preview Room	East Room, Third Floor	
Drinks Reception	Britten, Third Floor	

12 CPD Credits
Unique reference number 113109

BHIVA COMMITTEES

EXECUTIVE COMMITTEE

OFFICERS

Chair

Prof C Orkin Barts Health NHS Trust, London

Vice Chair

Prof C Leen Western General Hospital, Edinburgh

Honorary Secretary

Dr A Sullivan Chelsea and Westminster Hospital, London

Honorary Treasurer

Dr D Churchill Royal Sussex County Hospital, Brighton

MEMBERS

Prof B Angus University of Oxford

Dr F Burns Royal Free Hospital, London

Dr D Chadwick James Cook University Hospital, Middlesbrough

Dr M Chaponda University of Liverpool

Mr P Clift BHIVA Community Representative Trustee

Prof L Dorrell University of Oxford

Prof B Gazzard CBE Chelsea and Westminster Hospital, London

Dr Y Gilleece Royal Sussex County Hospital, Brighton

Dr R Kulasegaram St Thomas' Hospital, London

Dr N Mackie Imperial College Healthcare NHS Trust, London

Dr I Reeves Homerton University Hospital, London

Prof C Sabin University College London

Dr G Schembri Manchester Centre for Sexual Health

Dr S Taylor Birmingham Heartlands Hospital

Dr L Waters Mortimer Market Centre, London

CONFERENCES SUBCOMMITTEE

Dr L Waters Chair and BHIVA Executive Committee member

Dr I Reeves Vice Chair, Local Host BHIVA Autumn Conference 2017 and BHIVA Executive Committee member

Prof B Angus BHIVA Executive Committee member

Dr F Burns BHIVA Executive Committee member

Dr M Chaponda BHIVA Executive Committee member

Dr D Churchill BHIVA Executive Committee member

Mr P Clift BHIVA Executive Committee member and Community Representative

Prof B Gazzard CBE BHIVA Executive Committee member

Dr R Kulasegaram BHIVA Executive Committee member

Prof C Leen BHIVA Executive Committee member

Dr N Mackie BHIVA Executive Committee member

Prof C Orkin BHIVA Executive Committee member

Prof C Sabin BHIVA Education and Scientific Subcommittee Chair

Dr S Taylor BHIVA Executive Committee member

Mrs S Morris Invited representative

Dr M Tenant-Flowers Invited representative

Dr E Wilkins Invited representative

PROGRAMME SUMMARY

WEDNESDAY 15 NOVEMBER 2017

BHIVA Hepatology Highlights for the Healthcare Specialist in collaboration with the British Viral Hepatitis Group (BVHG).

1800–2015	Registration and Exhibition open
1830–1835	Welcome and Introduction
1835–1905	The role of resistance to HCV treatment in current practice
1905–1940	Does treating hepatitis lead to reversal of liver fibrosis?
1940–2010	What can hepatitis learn from HIV as we look to elimination?
2010–2030	Panel discussion
2030	Close

THURSDAY 16 NOVEMBER 2017

BHIVA Autumn Conference

0830–1830	Registration and Exhibition open
0855–0900	Welcome Address
0900–1000	ViiV Healthcare UK Satellite Symposium
1000–1030	BHIVA Foundation Lecture
1030–1100	Morning coffee
1100–1230	BHIVA Best Practice Management Session
1230–1400	Lunch
1240–1325	BHIVA Lunchtime Workshop
1255–1355	Janssen Lunchtime Workshop
1400–1500	BHIVA Plenary Session 1
1500–1600	BHIVA Plenary Session 2
1600–1630	Afternoon tea
1630–1715	BHIVA Community Symposium
1715–1815	MSD Ltd Satellite Symposium
1815–1915	Drinks Reception

FRIDAY 17 NOVEMBER 2017

BHIVA Autumn Conference

0815–1440	Registration and Exhibition open
0810–0855	Breakfast Workshop
0900–1000	Gilead Sciences Satellite Symposium
1000–1030	CHIVA Plenary Lecture
1030–1040	BHIVA Awards Ceremony
1040–1110	Morning coffee
1110–1140	Public Health England Lecture
1140–1210	BHIVA Standards of Care Session
1210–1240	BHIVA Audit Session
1240–1310	Gazzard Lectureship in HIV Medicine
1310–1330	BHIVA Annual General Meeting
1310–1440	Lunch
1335–1420	BHIVA / CHIVA Lunchtime Workshop
1335–1435	Gilead Sciences Lunchtime Workshop
1440–1540	BHIVA Plenary Session 3
1540–1640	BHIVA Clinical Conundrums
1640–1645	Close

PROGRAMME BHIVA AUTUMN CONFERENCE 2017

WEDNESDAY 15 NOVEMBER 2017

All sessions to be held in the Abbey, Fourth Floor, QEI Centre unless otherwise stated

Hepatology Highlights for the Healthcare Specialist in collaboration with the British Viral Hepatitis Group (BVHG)

Meeting Sponsors 2017



1800–2015	Registration and exhibition open
1830–1835	Welcome and Introduction Dr Sanjay Bhagani <i>Royal Free Hospital, London</i>
1835–1905	The role of resistance to HCV treatment in current practice Dr Emma Thomson <i>University of Glasgow</i>
1905–1940	Does treating hepatitis lead to reversal of liver fibrosis? Dr Douglas Macdonald <i>Royal Free Hospital, London</i>
1940–2010	What can hepatitis learn from HIV as we look to elimination? Dr Nathan Ford <i>World Health Organization, Geneva, Switzerland</i>
2010–2030	Panel discussion

THURSDAY 16 NOVEMBER 2017

All sessions to be held in the Fleming Room, Third Floor, QEI Centre unless otherwise stated

0830–1830	Registration and exhibition open
0855–0900	Welcome Address by the Chair of the British HIV Association Professor Chloe Orkin <i>Barts Health NHS Trust, London</i>
0900–1000	ViiV Healthcare UK Satellite Symposium (see page 11, for further information)
1000–1030	BHIVA Foundation Lecture Chair: Professor Chloe Orkin <i>Barts Health NHS Trust, London</i> How to survive a sexual health tender: the HIV clinic perspective Dr Orla McQuillan <i>Manchester Royal Infirmary</i> Dr Colm O'Mahony <i>Countess of Chester Hospital NHS Foundation Trust</i>
1030–1100	Morning coffee

PROGRAMME BHIVA AUTUMN CONFERENCE 2017

THURSDAY 16 NOVEMBER 2017

1100–1230

BHIVA Best Practice Management Session

Chairs: Dr Fiona Burns

Mortimer Market Centre, London

Dr Duncan Churchill

Sussex University Hospital NHS Trust, Brighton

Managing long-term opiates and hypnotics

Dr Ravneet Batra

Western General Hospital, Edinburgh

HIV testing

Dr Jonty Heaversedge

NHS England

Dr Cristina Guallar

NHS Southwark

HIV resistance testing, hot topics and recent developments

Dr Nicola Mackie

Imperial College Healthcare NHS Trust, London

1230–1400

Lunch and Lunchtime Workshops

1240–1325

BHIVA Lunchtime Workshop

Clinico-pathological case presentations

Facilitators: Professor Mark Bower

Chelsea and Westminster Hospital, London

Dr Ula Mahadeva

Guy's and St Thomas' NHS Foundation Trust

Dr Melinda Tenant-Flowers

Retired consultant in HIV and sexual health medicine

An interesting eruption

Dr Aaminah Verity

University Hospital Lewisham, London

An unexpected virus

Dr Francesca Ferretti

Chelsea and Westminster Hospital, London

No walk in the park

Dr William Hurt

Chelsea and Westminster Hospital, London

1255–1355

Janssen Lunchtime Workshop Abbey, Fourth Floor (see page 11, for further information)

1400–1500

BHIVA Plenary Session 1

Chairs: Dr Mas Chaponda

University of Liverpool

Professor Lucy Dorrell

University of Oxford

Premature ageing: is it really happening?

Dr Keri Althoff

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Anti-inflammatory agents in HIV

Dr Douglas Fink

University College London

PROGRAMME BHIVA AUTUMN CONFERENCE 2017

THURSDAY 16 NOVEMBER 2017

1500–1600

BHIVA Plenary Session 2

Chairs: Dr Ranjababu Kulasegaram

Guy's and St Thomas NHS Foundation Trust

Dr Ed Wilkins

North Manchester General Hospital

Living healthier, happier and wealthier – health improvement in the context of HIV

Dr Justin Varney

Public Health England

Point of care diagnostics

Professor Rosanna Peeling

London School of Hygiene and Tropical Medicine

1600–1630

Afternoon tea

1630–1715

BHIVA Community Symposium

Chairs: Mr Paul Clift

UK Community Advisory Board

Mrs Sheila Morris

NHS Lothian, Edinburgh

Ageing and HIV

Dr Robert James

Birchgrove

Dr Juliet Wright

Brighton and Sussex Medical School

Mr Clive Blowes

Terrence Higgins Trust

1715–1815

MSD Satellite Symposium (see page 11, for further information)

1815–1915

Drinks Reception and Welcome by Rt Hon Lord Fowler, the Patron of the BHIVA
Britten, Third Floor

FRIDAY 17 NOVEMBER 2017

All sessions to be held in the Fleming, Third Floor, QEl Centre unless otherwise stated

0815–1440

Registration and exhibition open

0810–0855

Breakfast Workshop: PrEP Impact Trial in England Abbey, Fourth Floor

Chair: Dr Ann Sullivan

Chelsea and Westminster Hospital, London

Dr Laura Waters

Mortimer Market Centre, London

Ms Hannah Reaney

St Stephen's AIDS Trust

Dr Will Nutland

PrEPster

0900–1000

Gilead Sciences Satellite Symposium (see page 11, for further information)

1000–1030

CHIVA Plenary Lecture: Breastfeeding in HIV-positive women

Chair: Dr Amanda Williams

North West London Hospitals NHS Trust

Dr Hermione Lyall

Imperial College Healthcare NHS Trust, London

PROGRAMME BHIVA AUTUMN CONFERENCE 2017

FRIDAY 17 NOVEMBER 2017

- | | |
|-----------|--|
| 1030–1040 | BHIVA Awards Ceremony
Professor Caroline Sabin
<i>University College London</i> |
| 1040–1110 | Morning coffee |
| 1110–1140 | Public Health England Lecture: Local response to eliminating HIV
Chairs: Dr Steve Taylor
<i>Heart of England NHS Foundation Trust, Birmingham</i>

Dr Sophie Candfield
<i>Mortimer Market Centre, London</i>

Dr Valerie Delpech
<i>Public Health England</i>

Dr Laura Waters
<i>Mortimer Market Centre, London</i> |
| 1140–1210 | BHIVA Standards of Care for People Living with HIV
Chairs: Dr Steve Taylor
<i>Heart of England NHS Foundation Trust</i>

Dr Sophie Candfield
<i>Mortimer Market Centre, London</i>

Dr Alison Howarth
<i>University College London</i>

Dr Ann Sullivan
<i>Chelsea and Westminster Hospital, London</i> |
| 1210–1240 | BHIVA Audit Session
Chairs: Dr David Chadwick
<i>James Cook University Hospital, Middlesbrough</i>

Dr Ann Sullivan
<i>Chelsea and Westminster Hospital, London</i>

Alcohol, substance misuse and psychological support
Dr Sarah Parry
<i>Barts Health NHS Trust, London</i> |
| 1240–1310 | Gazzard Lectureship in HIV Medicine
Chair: Professor Brian Gazzard
<i>Chelsea and Westminster Hospital, London</i>

Palliative care and HIV
Dr Richard Harding
<i>King's College London</i> |
| 1310–1330 | BHIVA Annual General Meeting (members only) |
| 1310–1440 | Lunch and Lunchtime Workshops |
| 1335–1420 | BHIVA/CHIVA Lunchtime Workshop
Pregnancy and breastfeeding case presentations
Facilitators: Dr Yvonne Gilleece
<i>Royal Sussex County Hospital, Brighton</i>

Dr Hermione Lyall
<i>Imperial College Healthcare NHS Trust, London</i>

Dr Amanda Williams
<i>London North West Hospitals NHS Trust</i>

Management of premature delivery in a pregnant woman with HIV drug resistance
Mrs Jessica Clements
<i>Kent Community Health NHS Trust</i> |

PROGRAMME BHIVA AUTUMN CONFERENCE 2017

FRIDAY 17 NOVEMBER 2017

A positive labour

Dr Nina Vora

Mortimer Market Centre

Multidisciplinary challenges in an unexpected pregnancy

Dr Larissa Mulka

Brighton and Sussex Medical School

1335–1435

Gilead Sciences Lunchtime Workshop Abbey, Fourth Floor (see page 11, for further information)

1440–1540

BHIVA Plenary Session 3

Chairs: Dr Gabriel Schembri

Central Manchester NHS Foundation Trust

Professor Clifford Leen

NHS Lothian, Edinburgh

HIV and neglected tropical diseases

Professor Brian Angus

University of Oxford

TB update

Dr Martin Dedicoat

Birmingham Heartlands Hospital



This lecture is funded by an independent educational grant from Oxford Immunotec.

Oxford Immunotec do not have any involvement in speaker selection or content of this lecture.

1540–1640

BHIVA Clinical Conundrums

Chairs: Dr Laura Waters

Mortimer Market Centre, London

Dr Muge Cevik

Western General Hospital, Edinburgh

Panellist: Dr Tristan Barber

Chelsea and Westminster Hospital, London

Bone and renal biomarkers

Dr Stephen Walsh

University College London

U=U: Talking to patients about transmission risk

Mr Matthew Hodson

NAM

Incidentalomas: how to deal with minor findings in the era of endless imaging

Dr Simon Jackson

NHS Lothian, Edinburgh

1640–1645

Close by the Chair of the British HIV Association

Professor Chloe Orkin

Barts Health NHS Trust, London

PROGRAMME OF SATELLITE SYMPOSIA AND SPONSORS' LUNCHTIME WORKSHOPS

THURSDAY 16 NOVEMBER

0900–1000

ViiV Healthcare UK Satellite Symposium

Personalised treatment in HIV: Adjusting to the ever-changing landscape

Chair: Professor Jan Van Lunzen

(University of Hamburg, Germany and University of Namibia, Medical School Windhoek)

Dr Charles Mazhude

Lewisham Hospital, London

Dr Sophie Forsyth

Great Western Hospital, Swindon

1255–1355

Janssen Lunchtime Workshop

How have considerations for choosing patients suitable for protease inhibitors changed?

Professor Chloe Orkin

Barts Health NHS Trust, London

Dr Laura Waters

Mortimer Market Centre, London

1715–1815

MSD Ltd Satellite Symposium

The evolving patient journey in HIV: a shared care and therapeutic perspective

Chair: Professor Jane Anderson

Homerton University Hospital, London

Dr Anton Pozniak

Chelsea and Westminster Hospital, London

Dr Yvonne Gilleece

Brighton and Sussex University Hospital

Dr Jonty Heaversedge

Southwark CCG and NHS England, London

Mr Shaun Watson

Chelsea and Westminster Hospital (HIV community), London and NHVNA

FRIDAY 17 NOVEMBER

0900–1000

Gilead Sciences Satellite Symposium

A case in point: therapy decisions in an era of choice

Chair: Dr Andrew Ustianowski

North Manchester General Hospital

Professor Bruce Hendry

Kings College London

Dr Iain Reeves

Homerton University Hospital, London

Dr James Cockburn

Royal Sussex County Hospital, Brighton

1335–1435

Gilead Sciences Lunchtime Workshop

A spotlight on bone health: screening, preventing and managing reductions in bone mineral density in an ageing HIV cohort

Dr Stephen Gallacher

NHS Greater Glasgow and Clyde

Dr Iain Stephenson

Leicester Royal Infirmary

TRIUMEQ is my treatment
DOLUTEGRAVIR▼ IS

MY CORE

START WITH TRIUMEQ—
powered by dolutegravir, offering your
patients all of the following:



CONFIDENCE

A potent regimen with **SUPERIOR EFFICACY** in treatment-naïve patients vs Atripla and atazanavir/r (in women)^{1,2}



DURABILITY

A dependable regimen with a **HIGH BARRIER TO RESISTANCE**¹⁻³



REASSURANCE

A convenient booster-free regimen with **FEW SIGNIFICANT DRUG-DRUG INTERACTIONS**³

Triumeq▼
dolutegravir/abacavir/
lamivudine

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

Prescribing Information

Triumeq▼ dolutegravir 50mg/abacavir 600mg/lamivudine 300mg tablets
See Summary of Product Characteristics before prescribing.

Indication: HIV in over 12 years and ≥ 40 kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. **Dose:** one tablet once daily with or without food. **Elderly:** Limited data in 65+ yrs. **Creatinine clearance** <50 ml/min or moderate/severe hepatic impairment: Not recommended. Monitor closely in mild hepatic impairment. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Triumeq without delay if HSR suspected. Never reintroduce any dolutegravir- or abacavir-containing product after suspected HSR. Risks of immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with etravirine (without boosted PI), efavirenz, nevirapine, rifampicin, boosted tipranavir, carbamazepine, oxcarbazepine, phenytoin, phenobarbital and St John's Wort).

Use with cladribine not recommended. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Caution with metformin: monitor renal function and consider metformin dose adjustment. **Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for details. Headache, insomnia, sleep/dream disorders, GI disturbance, fatigue, hypersensitivity, anorexia, depression, dizziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus, alopecia, arthralgia, myalgia, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicide attempt, rhabdomyolysis, lactic acidosis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. **Basic NHS costs:** 30 tablets: £798.16 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

[POM] S1A

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.

Date of approval: July 2017

Zinc code: UK/TRIM/0037/14(8)

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

References: 1. Walmsley S et al. *J Acquir Immune Defic Syndr*. 2015;70:515-519. 2. Orrell C et al. Published online July 17, 2017. *Lancet HIV*. doi: 10.1016/S2352-3018(17)30095-4. 3. TRIUMEQ Summary of Product Characteristics. January 2017.



TRIUMEQ is owned by or licensed to the ViiV Healthcare group of companies.
Atripla is owned by or licensed to Bristol-Myers Squibb & Gilead Sciences, LLC.
©2017 ViiV Healthcare group of companies or its licensor.

Date of preparation: October 2017 ViiV/DGR/0066/17e

CONFERENCE INFORMATION

BHIVA Autumn Conference: 16–17 November 2017

The registration fee gives access to the scientific sessions of the BHIVA Autumn Conference, including satellite symposia. All refreshments and lunches throughout the conference are included in the registration fee.

Sponsors' Lunchtime Workshops

Places are limited and will be restricted to 80 delegates per workshop. Places will be available on site, on a first-come, first-served basis, at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop.

Each workshop will begin promptly and refreshments will be provided for delegates attending these sessions.

Prizes and awards

The Don Jeffries BHIVA Research Award

BHIVA created this award in honour of the late Professor Don Jeffries. This will be awarded for the highest-scoring application, as judged by the BHIVA Research Awards Judging Panel, from the applications submitted for the 2017 BHIVA Research Awards. The award will be presented in the lecture theatre as part of the morning sessions on Friday 17 November 2017.

BHIVA Best Clinico-pathological and Best Pregnancy and Breastfeeding Case Presentations:

A prize will be awarded to the presenter of the best case for each of the above workshops. The prize will be presented at the end of each workshop.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will receive CPD credit at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, social events and satellite symposia). The conference will be allocated a maximum of 6 CPD credits per conference day.

CPD Accreditation: Credits attributed and unique reference number		
BHIVA Autumn	12 Credits	113109
Hepatology Highlights for the Healthcare Specialist. In collaboration with BVHG.	2 Credits	114015

BHIVA Community Registration

BHIVA has supported free registrations for over 50 community representatives to attend the conference.

BHIVA Registration Scholarships

BHIVA Registration Scholarships have been made available to 5 delegates, who are doctors and who are retired, not working or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or post-graduate work. The scholarships cover the conference registration fee.

BHIVA Registration Scholarships in collaboration with ViiV Healthcare UK

ViiV Healthcare in collaboration with the British HIV Association (BHIVA) have supported over 40 registration scholarships to assist non-consultant healthcare professionals (BHIVA members) to attend the BHIVA Autumn Conference. Applications have been reviewed by BHIVA and have been allocated on an assessment of merit. ViiV Healthcare UK have had no involvement in the selection of scholarship winners. BHIVA are very grateful to ViiV Healthcare for this support.

Cloakroom

A staffed cloakroom is available at the QEl Centre. All belongings are left at the owner's risk. The QEl Centre and the British HIV Association do not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom areas.

WiFi Connectivity

Free Wifi access will be available at the conference venue.

CONFERENCE INFORMATION

BHIVA Conferences App

BHIVA have developed a conference app which is downloadable from App Store for iPhone users or Playstore for Android devices. The app will provide users with the following facilities:

- Test the Chair (note all questions will be moderated).
- Voting for the three BHIVA case presentation workshops.
- Information on the conference programme speakers, sponsors and exhibitors.
- Ability to complete the Conference Evaluation Questionnaire via the app.

Social Media

Follow BHIVA on social media: BritishHIVAssociation • British HIV Association • @BritishHIVAssoc

Conference venue

QEI Centre

Broad Sanctuary · Westminster · London SW1P 3EE

☎ +44 (0)20 7222 5000 • 🌐 www.qeicc.co.uk

The conference venue is a short walk from **Westminster** or **St James's Park** underground stations. Please see the map for the location of these stations in relation to the **QEI Centre**.

Westminster and St James's Park underground stations are easily accessible from **King's Cross**, **St Pancras (Eurostar)** and **Victoria** main-line rail stations and can be accessed by the Jubilee line or the Circle and District lines. The journey from these main-line stations to Westminster or St James's Park underground stations takes approximately 10 minutes.

There are also good links to the city centre from both Heathrow and Gatwick airports. Journeys by either **Heathrow** or **Gatwick Express** take about 1 hour.


There are four car parks near to the conference venue. For further information please visit www.ncp.co.uk

Please note that the conference venue is located within the London Congestion Charge Zone.




EXHIBITION FLOOR PLAN AND EXHIBITORS

Hepatology Highlights Exhibition Floorplan, Rutherford, Fourth Floor



Autumn Exhibition Floorplan Britten, Third Floor



EXHIBITORS

- | | | |
|------------------------------|-----------------------------------|---------------------------------|
| 1 Gilead Sciences | 8 Body & Soul | 15 National AIDS Trust |
| 2 ViiV Healthcare UK Medical | 9 The Sophia Forum | 16 Positively UK |
| 3 Pasante | 10 NAM | 17 BHIVA Standards Consultation |
| 4 Saving Lives | 11 Shared Decision Making Project | 18 Mildmay |
| 5 Kora Healthcare | 12 MSD | 19 InTec Products Inc |
| 6 Terrence Higgins Trust | 13 ViiV Healthcare UK | 20 Janssen |
| 7 UK-CAB/ HIV iBase | 14 Oxford Immunotec | |

PLENARY SPEAKER BIOGRAPHIES

Keri Althoff is an Associate Professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health, with a joint appointment in the Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins School of Medicine. Her research focuses on ageing with HIV, monitoring the quality of HIV care in the US and Canada and approaches to longitudinal collaborative study designs that curate large data from sources, including electronic medical records. She is the co-director of the Epidemiology and Biostatistics Core of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

Brian Angus is Associate Professor and Reader in infectious diseases, in the Nuffield Department of Medicine, Oxford University and a Senior Clinical Scientist, with the MRC CTU. He is also Director of the Oxford University's Centre for Tropical Medicine and Global Health and NHS Clinical Lead for ID, in the Oxford Universities Hospital Trust. He is chairing the BHIVA guidelines committee on monitoring patients living with HIV.

Dr Tristan Barber is currently a Consultant at Chelsea and Westminster Hospital. He is Chair of the BASHH HIV SIG and also sits on the BHIVA Education and Scientific Subcommittee. He has a research background in HIV-related neurocognitive impairment.

Ravneet Batra is a Consultant Liaison Psychiatrist, with special interest in blood-borne viruses and is based at the Regional Infectious Diseases Unit in Edinburgh. Ravneet is passionate about improving mental health outcomes in patients with HIV and HCV through her involvement in policy guidelines, education and all aspects of delivery of care for mental health problems in this patient population.

Sanjay Bhagani is a Consultant Physician in infectious diseases and HIV medicine, at the Royal Free Hospital, London and Honorary Senior Lecturer in Infectious Diseases, at University College London. He is established and is the current lead of a multidisciplinary HIV/hepatitis co-infection service, at the Royal Free and is the current Chair of BHIVA's Viral Hepatitis Group. He serves on the HIV/Hepatitis guidelines subcommittees, for both BHIVA and the European AIDS Clinical Society. He serves on the editorial boards of AIDS Research and Therapy and BMC Hepatology, Medicine and Policy and is a trustee at AIDS Orphan.

Clive Blowes is the National Co-ordinator for Terrence Higgins Trust's flagship Health, Wealth and Happiness project, which supports people aged 50 or over living with HIV in London and Brighton. Clive has worked with older people living with HIV for the last 5 years, mainly mentoring and counselling, before moving to his current role. As a qualified counsellor, he is particularly interested in differences in psychological resilience that seemingly enable some people to cope better with their diagnosis.

Mark Bower is a Consultant Medical Oncologist at Chelsea and Westminster Hospital and Professor at Imperial College, who specialises in the treatment of AIDS-related malignancies. He has developed one of the largest centres for the management of these tumours in Europe, receiving referrals from throughout the UK and has cared for over 3000 patients with HIV-associated cancers. His clinical research covers the epidemiology, aetiology, pathogenesis and management of these tumours. He has a laboratory programme studying the immunopathology of these tumours, in collaboration with a number of basic scientists.

Martin Dedicoat is a Consultant in infectious diseases at Heart of England Foundation Trust, Birmingham. He is the clinical TB lead for Birmingham. Martin trained in infectious diseases in Birmingham, Ecuador and South Africa. His main research interest is in contact tracings.

Valerie Delpech is a Medical Epidemiologist based at Public Health England and leads a team of scientists and data managers to monitor the HIV epidemic and quality of care people living with HIV receive in the UK. Valerie's research interests focus on better understanding the epidemiology of HIV and STIs, and public health interventions to prevent these infections among vulnerable populations. She serves on a number of national and international committees in relation to HIV public health monitoring, prevention and policy development and is an executive trustee for the National AIDS Trust.

PLENARY SPEAKER BIOGRAPHIES

Douglas Fink is an Infectious Diseases and General Medicine Registrar based at the Hospital for Tropical Diseases, London. He is a Wellcome Trust Clinical Research Fellow at UCL, undertaking his PhD under the supervision of Professor Greg Towers, investigating the interaction of HIV and host innate immunity. He collaborates with the Nigerian Institute of Medical Research in Lagos, Nigeria, studying non-communicable diseases and use of non-prescription medicine, in a large cohort of PLWH. In the UK, he has a particular clinical research interest in the management of inflammatory conditions in PLWH.

Nathan Ford is a scientist with the Department of HIV/AIDS and the Global Hepatitis Programme of the WHO in Geneva. He is also head of WHO's Guidelines Review Committee. Prior to joining WHO, he worked with Médecins Sans Frontières (MSF) for 14 years supporting HIV programmes in a number of countries in southern Africa and South-east Asia. He holds a degree in Microbiology and Virology, a master's degree in Public Health and Epidemiology and a PhD in Clinical Epidemiology. He is Fellow of the Royal College of Physicians of Edinburgh and has published over 380 peer-reviewed publications. He is an editorial adviser, for WHO bulletin and is on the editorial boards of *the Journal of the International AIDS Society*, *Tropical Medicine and the International Health and Conflict and Health*.

Yvonne Gilleece is a Consultant in HIV Medicine at Brighton and Sussex University Hospitals NHS Trust. She has a special interest in HIV and hepatitis co-infection and liver dysfunction. She also specialises in HIV and women. She is Chair of SWIFT, promoting research in women living with HIV and is Chair of the BHIVA Pregnancy Guidelines.

Cristina Guallar is a GP in Southwark and a Speciality Doctor, in HIV at the Mortimer Market Centre in London. She completed her specialist training, in internal medicine and infectious diseases in Spain and moved to the UK, where she later trained as a GP. Cristina has since continuously worked, both in HIV and in general practice. From May 2017, she is the HIV Clinical Champion for Southwark CCG, with the aim of normalising HIV testing in the borough and wider South East London.

Richard Harding is the Herbert Dunhill Professor of Palliative Care and Rehabilitation, at King's College London. He is also Director of the Centre for Global Health Palliative Care. His research interests focus on person-centeredness and quality of life for people with long-term incurable conditions. His interest in HIV is best practice in the assessment and management of symptoms and concerns from disorders into the end of life and how best to incorporate the principles of palliative care into routine practice. This global programme has developed, validated and implemented patient-centred outcome measurement in HIV, cancer and other non-communicable diseases.

Jonty Heaversedge has been a GP in South East London since he qualified from the University of London, nearly 20 years ago. He is passionate about general practice, the value it brings to the health and social care system and the need to ensure that we have a high-quality, sustainable primary care service at the heart of the new models of care currently emerging across London. He currently works as a sessional GP, having been a partner in a GP practice in Southwark until 4 years ago when he became Chair of the CCG. He became involved in the commissioning of local health services in Southwark about 7 years ago, since that time he's become increasingly interested in the wider health and care system, and transforming the services that local people receive in South East London. He has recently been appointed as the Medical Director for Primary Care and Digital Transformation in London. Information and technology are key enablers of system transformation and Dr Heaversedge is incredibly excited about the opportunity this new role offers to support the development of integrated and continuously learning health and care systems across the London.

Matthew Hodson is the Executive Director of NAM (formerly known as National AIDS Manual), a UK community-based organisation and registered charity that supports people living and working with HIV by providing accurate, impartial, and up-to-date information about HIV/AIDS. NAM's portfolio includes aidsmap, one of the most highly regarded non-Governmental sources of HIV information globally. Prior to joining NAM Matthew was the Chief Executive of GMFA the gay men's health charity.

PLENARY SPEAKER BIOGRAPHIES

Alison Howarth is a Senior Research Associate, at the Institute for Global Health at UCL. Her PhD in Social Statistics, Methods and Computing, was an exploration of use of the internet for collecting data on sexual behaviour among gay and bisexual men in the UK. Since then, she has worked on various research projects, in the field of sexual health and HIV. She is currently working, as the Project Facilitator for the new BHIVA Standards of Care.

Simon Jackson is an Oncological Radiologist in Edinburgh, trying not to drown in a sea of incidental and largely clinically irrelevant imaging findings.

Robert James is a Lecturer in the School of Law at Birkbeck College and a member of the UKCAB. Like many academics, he mainly spends his time thinking about himself and has consequently, conducted research in the fields of HIV, haemophilia and hepatitis C. Having been recently cured of HCV and more importantly, become old he is now interested in the process of ageing, HIV and producing the patient summary of the Cobra study. When he was young, he worked as a social worker in the field of drug misuse and mental health.

Hermione Lyall is a Consultant in paediatric infectious diseases, at Imperial College Healthcare NHS Trust. Prevention of transmission of HIV from mother to infant and management of HIV-infected children are her main areas of clinical work. She is also interested in other congenital infections and their prevention. She is a member of the PENTA (Paediatric European Network for the Treatment of AIDS) steering committee and participates in HIV-treatment trials for children. She chaired the European Society for Paediatric Infectious Diseases (ESPID) training committee 2013–2016 and was awarded the ESPID medal for education 2016.

Douglas Macdonald graduated from the University of Southampton in 2001 with Honours and Distinctions in medical sciences and clinical medicine. He trained on the Hammersmith rotation and undertook specialist registrar training in gastroenterology and hepatology, based at Imperial College Hospital NHS Trust. He was awarded an MRC Clinical Research Fellowship in 2009, completing a PhD in virology and immunology at University College London followed by a fellowship at Yale University in 2012. He has been a Consultant Hepatologist at the Royal Free Hospital since 2014 and chairs the North Central London Hepatitis C Treatment network.

Nicola Mackie is a Consultant Physician and Head of Speciality for HIV at Imperial College Healthcare NHS Trust. Her research was in the field of HIV-1 drug resistance and she runs the weekly Virtual Clinic. She is involved with writing national guidelines, examining for dipHIV, teaching for BASHH and EACS, the SWIFT collaboration (Supporting Women with HIV Information Network) and is a Trustee member of the BHIVA Executive Committee.

Ula Mahadeva is a Consultant Histopathologist at Guy's and St Thomas' NHS Foundation Trust, where her areas of subspecialisation are gastrointestinal histopathology, gynaecological and non-gynaecological cytopathology, consented and maternal death autopsies and infectious disease histopathology. She is known within the department and region for her enthusiasm for teaching and training, including helping trainees with preparation for the FRCPath examination and is an RCPPath examiner.

Orla McQuillan is a Consultant in the Northern Sexual Health Service in Manchester. She has wide experience of winning and losing sexual health tenders, which she is willing to share with anyone who will listen.

Colm O'Mahony is a Consultant in Chester in sexual health and HIV. He qualified in Ireland with a BSc then completed medicine, followed by an MD in immunology. As there was no sex in Ireland, he came to Liverpool in 1986 to study venereology. He looked after HTLV111 patients in the 1980s, until the Americans fessed up and it became known as LAV, then HIV. He was chair of AGUM and he forced the merger with MSSVD to form BASHH. He set up and chaired the media group for BASHH and was on the BHIVA executive committee. He has railed against the folly of the wasted millions, spent on the destructive tendering of STD services. Transferring of services to local councils, who are used to tendering for grass cutting, bin emptying and parking fines has been a disaster. The split from HIV services is sad, for staff and patients.

PLENARY SPEAKER BIOGRAPHIES

Chloe Orkin is Chair of the British HIV Association and Consultant Physician at the Royal London Hospital where her clinical duties include running a busy HIV and HIV/ HCV research unit. Her specialist interests are: Anti-retroviral therapy, hepatitis and oncology. She has 90 peer-reviewed publications and has co-authored four British HIV Association guidelines on: Anti-retroviral therapy, Hepatitis, Malignancy and Routine Monitoring. Professor Orkin is the External Examiner to the Diploma in HIV Medicine. She is actively researching ways of implementing HIV and blood-borne virus testing. She was elected as BHIVA Chair in 2016 for a 3-year term.

Sarah Parry is a Specialty Registrar in GU medicine and HIV at the Royal London Hospital. She is a member of the BHIVA Audit sub-committee and worked on the 2017 national audit, of psychological wellbeing and use of alcohol and other drugs. She was SpR lead of the Going Viral campaign, researching blood-borne virus testing within the emergency department, for which she was awarded the 'Margaret Johnson' Best Oral Presentation Award at the 2017 Annual BHIVA conference.

Rosanna Peeling is currently Professor/Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine and Director of the International Diagnostics Centre (IDC). Trained as a medical microbiologist, she was Research Co-ordinator and Head of Diagnostics Research at WHO in Geneva and Chief of the National Laboratory for Sexually Transmitted Diseases in Canada, before assuming her current position. Her research focuses on defining unmet diagnostic needs and facilitating test development, evaluation and implementation in developing countries. She established the IDC to advocate the value of diagnostics, foster innovation and accelerate access, to quality-assured diagnostics worldwide.

Ann Sullivan trained in Australia and London, gaining an MD in HIV immunology. She is currently a Consultant at Chelsea and Westminster Hospital, where she is HIV Service Lead for the Kobler clinic, and an Honorary Senior Lecturer at Imperial College. Her specific interests include expanding HIV testing, MSM sexual health and utilising technology to improve patient care and experience. Dr Sullivan was elected as BHIVA Honorary Secretary in 2016 and is currently involved in revising the HIV Standards of Care and HIV Testing Guidelines and the development of HIV-specific PROMS.

Melinda Tenant-Flowers retired as Consultant in HIV/Sexual Health at King's College Hospital, London in 2015. Her research interests included HIV oncology, HIV testing and educational assessment. She contributed to the BHIVA Guidelines for Malignancy (2014), Monitoring (2015) and PrEP (2017). She has an MSc in Medical Education, leads BHIVA E-Learning CPD and is a member of BHIVA Education/Scientific, Conferences and Website Subcommittees. As an examiner for the Diplomas in HIV and GU Medicine, she was Convenor of the Diploma in GU Medicine, STC Co-Chair and ARCP/PYA representative (London), contributing to the 2016 GU/HIV SAC/RCP training curriculum and will contribute to the next curriculum revision.

Emma Thomson is an infectious diseases Physician and Clinical Senior Lecturer in Virology, in Glasgow. She runs a co-infection treatment clinic in Glasgow and a laboratory, funded by the Wellcome Trust and the MRC that carries out research into HCV immunity using next-generation sequencing and functional B and T cell assays. She is a member of the WHO HCV treatment, guidelines committee.

Justin Varney leads Public Health England's (PHE) work to improve the health and wellbeing, of working age adults and reduce health inequalities in this group. This portfolio includes leading PHE's work on physical activity, health, worklessness, workplace health, tackling LGBT health inequalities, as well as managing the teams leading their work on sexual, reproductive health and HIV prevention, community pharmacy and allied health professionals.

Stephen Walsh is a Senior Lecturer in experimental medicine and Honorary Consultant Nephrologist at the UCL Centre for Nephrology, Royal Free Hospital. He spent 2.5 years researching molecular physiology and eating lunch in Nice, France and completed his PhD in 2009. His research interest is mainly in the molecular physiology of sodium and acid transport in the renal tubule, especially in its relationship to hypertension. He is also interested in metabolic diseases in transplant patients and the relationship between hereditary renal tubular acidosis, red cell disease and human resistance to malaria.

PLENARY SPEAKER BIOGRAPHIES

Laura Waters is a Consultant at the Mortimer Market Centre in London where she is HIV and Hepatitis Service Lead and principal investigator for several antiretroviral trials. She was Vice-Chair of the 2015 BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy and now chairs this group. She is Chair of the BHIVA Conferences subcommittee and previous Chair of the BASHH HIV Special Interest Group. She is BASHH rep on the HIV CRG, vice-chair HIV London leads group and a THT trustee.

Amanda Williams has been a Consultant Paediatrician and Specialist in Paediatric Infectious Diseases at London North West Healthcare NHS Trust since 2002. She is lead for paediatric HIV and tuberculosis. Amanda has previously been Honorary Secretary of CHIVA and Chair of the CHIVA guideline group. She is a co-author of the CHIVA standards of care. She is the current Chair of the Children's HIV Association.

Juliet Wright is a Senior Lecturer and Honorary Consultant in elderly medicine at Brighton and Sussex Medical School (BSMS). She trained at Guy's and St Thomas' Hospitals and then in general and geriatric medicine in the South Thames region. She was awarded her MD from the University of Surrey for research involving recombinant human growth hormone in the pre-operative optimisation of elderly orthopaedic patients. Her current research studies focus on the assessment of frailty in the elderly HIV population and the barriers and facilitators to testing for HIV in older patients; she is supervising two PhD students in this area. Alongside the clinical team at BSUH, she has supported the development of the Silver clinic for older patients with HIV. Over the past year, Dr Wright has furthered her clinical interest in frailty and with Professor Malcolm Reed, has developed a joint medical and surgical clinic for the assessment of older and frail patients with breast cancer. She has a research interest in the management of hypertension in older people with respect to cognition and the accurate assessment and management of depression. She has received grants from NIHR, as well as from industry. Dr Wright is the Director of Undergraduate Teaching and Learning, at Brighton and Sussex Medical School.

FORTHCOMING EVENTS AND MAJOR SPONSORS 2017

FORTHCOMING EVENTS

BHIVA World AIDS Day

Friday 1 December 2017
The National Gallery Theatre, London
Register now at www.bhiva.org

Fourth Joint Annual Conference of the British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASHH)

17–20 April 2018
Edinburgh International Conference Centre (EICC)

BHIVA Autumn Conference

4–5 October 2018
QEII Centre, London

BHIVA 'Best of CROI' Feedback 2018

Monday 19 March 2018, London
Tuesday 20 March 2018, Birmingham
Wednesday 21 March 2018, Haydock
Tuesday 27 March 2018, Cardiff
Wednesday 28 March 2018, Wetherby
Thursday 29 March 2018, Edinburgh

BHIVA MAJOR SPONSORS 2017

Gilead Sciences Ltd

280 High Holborn
London
WC1V 7EE



Janssen

50–100 Holmers Farm Way
High Wycombe
Buckinghamshire HP12 4DP



MSD Ltd

Hertford Road
Hoddesdon
Hertfordshire EN11 9BU



ViiV Healthcare UK Ltd

Stockley Park West
Uxbridge
Middlesex UB11 1BT



For further information please contact:

BHIVA Conference Organisers

Mediscript Ltd

1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD
Tel: 020 8369 5380 Fax: 020 8446 9194
Email: bhiva@bhiva.org Web: www.bhiva.org

Download the BHVA Conferences App





**Fourth Joint Conference of the British HIV Association (BHIVA)
with the British Association for Sexual Health and HIV (BASHH)
17-20 April 2018, Edinburgh International Conference Centre, UK**

IMPORTANT DATES

REGISTRATION OPEN: FRIDAY 24 NOVEMBER 2017

ABSTRACT SUBMISSION & EARLY REGISTRATION DEADLINE: FRIDAY 19 JANUARY 2018

PROVISIONAL CONFERENCE TOPICS

Modern malignancies in HIV and sexual health

HIV cure overview, ethics and markers

BHIVA/BASHH Review Session

Advances in HIV care for 2018

Advances in sexual health for 2018

Advances in general medicine for 2018

BHIVA/BASHH Audit Session

Oral Research Presentations

Blood borne virus resistance challenges in the modern era

Safeguarding in HIV and sexual health

Telling the truth: issues around disclosure of sexually transmitted infections

BHIVA/BASHH Poster Session

BHIVA/BASHH Guidelines Session

Clinico-pathological case presentations workshop

Digital technologies, HIV and STI's

Health Protection Research Unit: blood borne and sexually transmitted infections

The refugee crisis covering an overview of issues relating to both HIV/STI's and TB

PrEP Question Time

Young people with HIV: the challenges with transition

Infectivity issues for MSM in people living with HIV

Syphilis epidemic/congenital syphilis & prophylaxis

Overheard at the gym: a clinician's overview of interactions/toxicities of commonly used drugs

BHIVA World AIDS Day Event

HIV Monologues

Written by Patrick Cash, directed by Luke Davies

'A hilarious and poignant play
- British Theatre

'Another triumph from the
team that have so successfully put
the spirit of community
into modern theatre'
- Gay Times

Register at www.bhiva.org

Registration is offered to all on a
complimentary basis

Friday 1 December 2017

18:30 – 21.00

The Sainsbury Wing at
The National Gallery Theatre, London

BHIVA MAJOR SPONSORS 2017





QRISK3: WHAT'S NEW AND WHAT DOES THIS MEAN FOR YOUR HIV PATIENTS?

AN INTERVIEW WITH DR JAMES COCKBURN, SUSSEX CARDIAC CENTRE, BRIGHTON, UK

■ **Dr James Cockburn** is a Consultant Cardiologist at the Sussex Cardiac Centre, the tertiary teaching hospital of the Brighton and Sussex University Trust in Brighton. He is an adult general cardiologist with a subspecialty in coronary intervention and structural heart disease. Dr Cockburn also has an interest in cardiovascular disease in patients with HIV for which he runs a joint clinic with an HIV physician.

We spoke with Dr Cockburn to discuss the recent publication of QRISK3,¹ the new factors identified for determining risk of cardiovascular disease, and how QRISK3 impacts patients with HIV.

What is QRISK?

QRISK is an algorithm that uses an individual's general health and social setting to estimate their 10-year risk of cardiovascular disease (CVD).¹

The aim is to identify patients at high risk ($\geq 10\%$) of developing CVD, and initiate preventative treatment.²

- The first QRISK algorithm was created in 2007.¹
- A second version, with additional risk factors, was introduced in 2008 (QRISK2).¹

As well as including standard risk factors, QRISK2 identified additional important CV risk factors that vary across the UK such as social class, deprivation and high-risk ethnic groups. Since 2008, the QRISK2 model has been annually recalibrated to reflect changes in population statistics (such as changes in the prevalence of smoking) and improvements in the quality of data available.¹ CVD risk scoring remains an area of contention as overprediction leads to preventative treatment in patients with nothing to gain, yet if the model underestimates risk then the opportunity for intervention and prevention of CVD in some patients is missed.

Why was QRISK3 developed?

In 2014, The National Institute for Health and Care Excellence (NICE) guideline was published on the risk assessment and reduction of CVD and it recommended the use of QRISK2 to assess an individual's risk of CVD.² However, NICE also highlighted conditions with a known increased risk of CVD that were not captured by the QRISK2 algorithm, such as patients with stage 3 chronic kidney disease (CKD) and those with HIV, and stated that a risk assessment tool should not be used in patients with the former.² Published research highlighted other conditions linked to increased CV risk that were also not included in QRISK2, such as erectile dysfunction, migraine, severe mental illness, use of antipsychotics or corticosteroids and blood pressure variability.¹

Box 1. QRISK2 risk factors and additional factors investigated for inclusion in QRISK3¹

QRISK2-2017 risk factors	Proposed QRISK3 risk factors
<ul style="list-style-type: none"> • Age • Ethnic origin • Deprivation (Townsend score) • Systolic blood pressure • BMI • Total cholesterol: HDL cholesterol ratio • Smoking status • Family history of coronary heart disease in a first degree relative <60 years old • Diabetes • Treated hypertension • Rheumatoid arthritis • Atrial fibrillation • CKD (stage 4 or 5) and major chronic renal disease 	<ul style="list-style-type: none"> • GP recorded diagnosis of CKD stage 3 • Systolic blood pressure variability • Migraine • Corticosteroid use • Systemic lupus erythematosus • Second generation atypical antipsychotic use • Severe mental illness • ED or treatment for ED • HIV or AIDS

CKD: chronic kidney disease; ED: erectile dysfunction; HDL: high density lipoprotein

Due to the increasing number of conditions not captured by QRISK2, the investigators decided to derive and validate a new algorithm (QRISK3) that included additional factors to better identify patients at high risk of CVD (see Box 1).¹

Data from 7.89 million patients across England were used to derive QRISK3, and the updated algorithm was validated using a further 2.67 million patients.¹

What does QRISK3 mean for HIV physicians and patients?

During the validation, all proposed QRISK3 risk factors shown in Box 1 were found to have significant prognostic value in CVD and were included in the final QRISK3 algorithm, **except HIV or AIDS**.¹

Despite growing evidence that people with HIV are at greater risk of CVD, HIV as a risk factor in QRISK3 did not reach statistical significance (although a tendency towards increased risk was observed).¹ The QRISK3 authors suggest this may be because:¹

- The relatively small number of patients with HIV/AIDS recorded on the general practice clinical system.
- People with HIV/AIDS tend to be younger, with shorter periods of follow-up and so the long-term association with CV risk is underestimated.
- Patients may be seen in specialist clinics rather than general practices, so fewer prescriptions are recorded on the QResearch database used to develop and validate QRISK3.

How would I use QRISK3 with my patients who have HIV/AIDS?

Despite a diagnosis of HIV/AIDS not being included in the QRISK3 assessment, it is still important that CV risk is estimated in these patients. This assessment tool provides an opportunity for all HIV patients to be assessed for 10-year CV risk using QRISK3 at their yearly review with a nurse specialist or HIV physician or in a joint clinic. Depending on their QRISK3 score, they should be either counselled about lifestyle choices, given appropriate primary prevention in the form of tight blood pressure and blood sugar control and lipid management, or referred to a cardiologist or specialist clinic (see Box 2). If at any time the patient complains of chest pains or tightness on exertion, they should be referred to a cardiologist for further investigation.

Future recommendations

Due to disease, the population of patients with HIV tend to be biologically older than their chronological age, and advances in treatment mean that patients are now living longer. Most patients with HIV are regularly seen by specialists and consultants, which means that comorbidities tend to be identified and treated early. The health data available for this patient group are growing, and future risk algorithms will be able to draw from these data and more accurately determine probabilities of future disease. As a result, it is possible that HIV/AIDS may be included in future versions of QRISK (either as a diagnosis or related to medication). HIV specific risk scores could be run in parallel, such as the DAD (Data Collection on Adverse Effects of Anti-HIV Drugs).^{3,4}

Summary

Although HIV/AIDS is not part of the final QRISK3 algorithm, the inclusion of additional variables that are comorbidities in these patients, such as CKD stage 3 and erectile dysfunction, will help physicians to more accurately identify those with high risk of heart disease and stroke, and may offer additional insights into the CV health of your patients with HIV ■

References

1. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ* 2017; **357**: j2099.
2. National Institute for Health and Care Excellence (NICE). *Cardiovascular disease: risk assessment and reduction, including lipid modification*. CG181. London: NICE, 2014. www.nice.org.uk/guidance/cg181 (last accessed 21/08/17)
3. Friis-Møller N, Thiebaut R, Reiss P *et al*. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil* 2010; **17**: 491–501.
4. Centre of Excellence for Health, Immunity and Infections. Clinical risk scores. www.chip.dk/Tools (last accessed 06/09/17)

■ Box 2. Using QRISK3 to predict cardiovascular risk in patients with HIV/AIDS

